United Gene High-Tech Group Limited announced the board will inform based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended December 31, 2013, the group is expected to record a substantial increase in the consolidated net loss for the six months ended December 31, 2013 as compared with the corresponding period in 2012, due to a loss on the acquisition of the convertible bonds issued by Extrawell Pharmaceutical Holdings Limited.
Innovative Pharmaceutical Biotech Limited
Equities
399
BMG4783W1073
Industrial Machinery & Equipment
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.21 HKD | 0.00% | +5.53% | -4.11% |
05-31 | Innovative Pharma Extends Long Stop Date for Convertible Bond Issuance | MT |
2023 | Innovative Pharmaceutical Biotech Returns to Fiscal H1 Attributable Profit | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.11% | 46.33M | |
+7.67% | 43.13B | |
-1.36% | 36.65B | |
+8.38% | 7.25B | |
+17.53% | 7.13B | |
-15.73% | 4.79B | |
+19.26% | 1.46B | |
-3.17% | 1.43B | |
+0.16% | 1.4B | |
+14.80% | 1.09B |
- Stock Market
- Equities
- 399 Stock
- News Innovative Pharmaceutical Biotech Limited
- United Gene High-Tech Group Limited Provides Earnings Guidance for the Six Months Ended December 31, 2013